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Abstract
Mammalian SWI/SNF complexes utilize either BRG1 or BRM as alternative catalytic subunits
with DNA-dependent ATPase activity to remodel chromatin. Although the two proteins are 75%
identical, broadly expressed, and have similar biochemical activities in vitro, BRG1 is essential for
mouse embryonic development, while BRM is dispensable. To investigate whether BRG1 and
BRM have overlapping functions during mouse embryogenesis, we performed double-
heterozygous intercrosses using constitutive null mutations previously created by gene targeting.
The progeny of these crosses had a distribution of genotypes that was significantly skewed relative
to their combined gene dosage. This was most pronounced at the top and bottom of the gene
dosage hierarchy with a 1.5-fold overrepresentation of Brg1+/+;Brm+/+ mice and a corresponding
1.6-fold underrepresentation of Brg1+/−;Brm−/− mice. To account for the underrepresentation of
Brg1+/−;Brm−/− mice, timed matings and blastocyst outgrowth assays demonstrated that ~50% of
these embryos failed to develop beyond the peri-implantation stage. These results challenge the
idea that BRG1 is the exclusive catalytic subunit of SWI/SNF complexes in ES cells and suggest
that BRM also interacts with the pluripotency transcription factors to facilitate self-renewal of the
inner cell mass. In contrast to implantation, the Brm genotype did not influence an exencephaly
phenotype that arises because of Brg1 haploinsufficiency during neural tube closure and that
results in peri-natal lethality. Taken together, these results support the idea that BRG1 and BRM
have overlapping functions for certain developmental processes but not others during
embryogenesis.
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Introduction
The mammalian genome is packaged as chromatin, and the most fundamental unit is the
nucleosome, which consists of a 147-bp segment of DNA wrapped around an octamer of
histones (Kornberg and Lorch 1999). Because nucleosomes are separated by short (10–90
bp) DNA linkers, they are ubiquitous and number ~3 × 107 per nucleus in mammalian cells.
Although nucleosomes and higher-order chromatin structures help compact the genome and
maintain its organization, they present major challenges for transcription, DNA replication,
and DNA repair. To counteract the effects of chromatin and facilitate these DNA-templated
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processes, four families of chromatin-remodeling complexes (SWI/SNF, ISWI, NuRD/Ni-2/
CHD, and INO80) are recruited to numerous sites in the genome where they harness the
energy of ATP hydrolysis to alter nucleosome position (Cairns 2007, Flaus and Owen-
Hughes 2011, Hota and Bartholomew 2011).
Mammalian SWI/SNF complexes consist of 9–12 subunits and utilize either BRG1 (also
known as SMARCA4) or BRM (also known as SMARCA2) as their catalytic subunit with
DNA-dependent ATPase activity (de la Serna et al 2006, Ho and Crabtree 2010). When
recruited to promoters by sequence-specific transcription factors, SWI/SNF complexes slide
or evict nucleosomes away from transcriptional start sites to regulate RNA Polymerase II
occupancy and transcriptional initiation (Liu et al 2011). Although BRG1 and BRM are able
to slide or evict nucleosomes on their own as recombinant proteins in cell-free systems
(Phelan et al 2000), their chromatin-remodeling activity is enhanced in the presence of
additional SWI/SNF subunits [often referred to as BAFs (BRG1 or BRM associated factors)
followed by a number corresponding to their molecular weight in kDa] (Phelan et al 1999).
Based on gene-targeting experiments in mice, the BRG1, SNF5/BAF47, BAF155, and
BAF250A/ARID1A subunits are required during the peri-implantation stage (Bultman et al
2000, de la Serna et al 2006, Gao et al 2008, Guidi et al 2001, Ho and Crabtree 2010, Kim et
al 2001, Klochendler-Yeivin et al 2000, Roberts et al 2000). This is compatible with the
pluripotency transcription factors SOX2, OCT4, and Nanog recruiting a SWI/SNF
subcomplex, called esBAF, to downstream target genes in embryonic stem (ES) cells to
facilitate their pluripotency and self-renewal (Gao et al 2008, Ho et al 2009a, Ho et al
2009b, Kaeser et al 2008, Kidder et al 2009, Yan et al 2008). This complex also participates
in the conversion of fibroblasts into induced pluripotent stem (iPS) cells (Singhal et al
2010). In addition, the BAF180/PBRM1 subunits and BAF60C are required for
cardiovascular development and survival beyond the mid-gestation stage (Bruneau 2010, de
la Serna et al 2006, Ho and Crabtree 2010, Lickert et al 2004, Wang et al 2004). In this case,
it is the cardiogenic transcription factors TBX5, GATA4, and Nkx2–5 that interact with
SWI/SNF to program non-cardiac mesoderm into cardiomyocytes (Bruneau 2010, Takeuchi
and Bruneau 2009). SWI/SNF complexes participate in many other developmental processes
based, in part, on an allelic series of Brg1 mutations generated by Cre/loxP conditional gene
targeting and ENU mutagenesis (Table 1).
From these gene-targeting experiments, the BRM subunit is a notable exception because
Brm null homozygotes are viable and fertile (Reyes et al 1998). Several lines of evidence
suggest that Brg1 can functionally compensate for the loss of Brm in these mice: 1, the two
proteins are 75% identical and have similar biochemical activities in vitro (Chiba et al 1994,
Phelan et al 2000); 2, BRG1 protein levels are elevated in Brm−/− tissues (Reyes et al 1998);
3, Brg1 is expressed at much higher levels than Brm in the early embryo (Bultman et al
2000, LeGouy et al 1998), and esBAF incorporates BRG1 as the catalytic subunit rather
than BRM (Ho et al 2009b). It is currently unclear whether Brm functions during
embryogenesis. On the one hand, it might not since BRG1 is expressed at higher levels in
undifferentiated cells that are highly proliferative, whereas BRM is enriched in
differentiated cells that are less proliferative (Reisman et al 2005). Furthermore, RNAi
knockdown experiments have shown that BRG1 and BRM can have opposing functions in
tissue-culture cells with BRG1 inhibiting differentiation and BRM promoting differentiation
(Flowers et al 2009). These findings suggest BRM might be more important for maintaining
homeostasis in adult cells as supported by a recent cardiovascular study (Willis et al 2012).
On the other hand, Brm might participate in certain developmental processes during
embryogenesis, but null mutants do not exhibit an obvious phenotype because of Brg1
functional compensation. To distinguish between these possibilities, we have analyzed
Brg1-Brm double mutants at different stages of development. As we report here, Brm is
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required to prevent implantation defects but not neural tube defects in Brg1 heterozygotes.
These findings suggest that Brm participates in a subset of developmental processes that are
sensitive to Brg1 dosage.
Materials and methods
Mice
All mouse experiments were approved by the Institutional Animal Care and Use
Committees (IACUC) review board at the University of North Carolina at Chapel Hill and
were performed in accordance with federal guidelines. The Brg1 and Brm mutant lines have
been characterized previously (Bultman et al 2000, Reyes et al 1998). For timed matings,
noon of the day that each copulation plug was detected was considered E0.5.
Blastocyst outgrowth analyses
Double heterozygotes were intercrossed, and E3.5 blastocysts were flushed from the uterine
tract. Blastocysts were placed in 10 µL of ES cell media (DMEM, 15% FCS) in Nunc dish
microwells (Nalgene, Palo Alto, CA) and grown under paraffin oil in 5% CO2 at 37 °C.
After 7 days, explants were scored for degree of outgrowth, photographed, and genotyped
by PCR.
Genotyping
Tail biopsies, embryos, and blastocyst outgrowths were digested in 200 µg/mL Proteinase K
in 50 mM Tris (pH 8.8), 1 mM EDTA (pH 8), and 0.5% Tween 20 at 55 °C. Lysates were
PCR amplified with the following cycling parameters: 94 °C for 1 min, 55 °C for 1 min, and
72 °C for 1 min for 35 cycles. The Brg1 primers were: 5’-cagtcatagccgaatagcct-3’, 5’-
gcagtttgtaagtcacaggc-3’, 5’-ttggagtggctggtgtccctgtaca-3’, 5’-tgatgaggaaaggcccgttgatgcg-3’
with the first two primers amplifying a 194-bp mutant fragment and the last two primers
amplifying a 176-bp wild-type fragment. The Brm primers were: 5’-
ctggactgccagctgcagag-3’, 5’-cctgagtcatttgctatagcctgtg-3’, and catcgccttctatcgccttc-3’, which
amplified a 310-bp wild-type fragment and a 700-bp mutant fragment. PCR products were
resolved on 2% agarose gels.
Cell culture, RNAi, and Western blot analyses
Normal human fibroblasts that ectopically express the catalytic subunit of telomerase
(NHF1-hTERT) were cultured under standard conditions (DMEM/10%FBS at 37 °C and
5% CO2), and RNAi-mediated protein depletion was performed using validated Smartpool
siRNAs (M-010431 and M-017253 from Dharmacon, Layfayette, CO) introduced by
electroporation. Western blot analyses were performed following standard procedures using
urea lysates and the following antibodies: J1 (kindly provided by Drs. Weidong Wang and
Gerald Crabtree), BRG1 (Santa Cruz G-7), BRM (Abcam 15597), and Tubulin (Sigma
T6793).
Results
Brg1+/−;Brm−/− double-mutant mice are underrepresented
To investigate whether there is a combined gene dosage requirement for the BRG1 and
BRM catalytic subunits, we performed double-heterozygous (Brg1+/−;Brm+/−) intercrosses
and genotyped the progeny at weaning. Because Brg1−/− is embryonic lethal (Bultman et al
2000), 6 genotypic categories were observed instead of 9 (Table 2). The absence of Brg1−/−
mice on a Brm−/− background (in addition to Brm+/+ and Brm+/− backgrounds) eliminated
the possibility of a functionally antagonistic relationship. Although we did not expect the
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Brg1−/− embryonic-lethal phenotype to be suppressed by Brm deficiency, it had been a
formal possibility, especially since BRG1 expression is often associated with
undifferentiated cells that are highly proliferative, whereas BRM expression is enriched in
differentiated cells that are less proliferative. Of the six genotypic categories, the one with
the lowest combined gene dosage (Brg1+/−;Brm−/−) was underrepresented by 39% (Table 2).
Furthermore, a significant proportion of the Brg1+/−;Brm−/− double-mutant mice that did
survive to weaning were runted (Figure 1). However, the runted animals were fertile upon
reaching sexual maturity (data not shown). Interestingly, the underrepresentation of the
Brg1+/−;Brm−/− category did not result in overrepresentation of the other 5 categories of
mice to similar extents. On the contrary, the other categories were either underrepresented or
overrepresented in a manner that was correlated with their combined gene dosage (Table 2).
For example, mice with the next lowest combined gene dosage (Brg1+/−;Brm+/−) were
underrepresented by 17% (Table 2). In contrast, Brg1+/+;Brm+/+ mice with the highest
combined gene dosage were overrepresented by 1.5-fold compared to what was expected
(Table 2).
Brm compensates for Brg1 haploinsufficiency during development in a tissue-specific
manner
To determine at which stage of development Brg1+/−;Brm−/− double mutants die, we
performed additional double-heterozygous intercrosses but as timed matings and genotyped
embryos. Dissections at embryonic day (E) E15.5–18.5 of gestation yielded results similar to
the genotype data at weaning because those embryos with the lowest combined gene dosage
were significantly underrepresented while embryos with the highest combined gene dosage
were significantly overrepresented (Table 3). A subset of Brg1+/− embryos are known to
exhibit exencephaly (Bultman et al 2000), but the incidence of this incompletely penetrant
phenotype was neither increased nor decreased in Brg1+/−;Brm−/− double-mutants compared
to Brg1+/− embryos on a Brm+/+ or Brm+/− background (Table 3). These findings indicate
that Brg1+/−;Brm−/− double mutants do not have an increased incidence of either
exencephaly or peri-natal lethality.
Dissections at E5.5–8.5 demonstrated that Brg1+/−;Brm−/− double mutants are already
significantly underrepresented at this early stage of embryogenesis (Table 3). In addition to
the 140 embryos that were genotyped at this stage, 11 empty deciduae were observed that
could not be genotyped because of maternal contamination. If these empty deciduae were
from Brg1+/−;Brm−/− embryos that failed to implant properly, then this genotypic class
would have been represented at the expected frequency (25/151 = .166 versus .167
expected). To explore this possibility, we performed blastocyst outgrowths. Following
double-heterozygous intercrosses, blastocysts were isolated, cultured for 7 days ex vivo,
photographed under a dissection microscope, and then genotyped. Two types of outgrowths
were observed in these experiments. Normal outgrowths hatched from the zona pellucida,
trophoblast giant cells from the trophectoderm attached to and spread out across the tissue
culture wells, and inner cell masses (ICM) underwent extensive cell proliferation (Figure
2A). These events recapitulate certain aspects of peri-implantation development. In contrast,
abnormal outgrowths did not hatch from the zona pellucida and neither the trophectoderm
nor the ICM showed any signs of growth (Figure 2B). Unlike the other genotypic classes, in
which >90% of the blastocyst outgrowths were normal, only 40% of the Brg1+/−;Brm−/−
double mutant blastocysts gave rise to normal outgrowths, whereas 60% were abnormal
(Figure 2C). These results support the idea that Brg1+/− blastocysts on a Brm-deficient
background are susceptible to implantation defects. This situation is similar to the
implantation defect of Brg1−/− blastocysts except the penetrance was ~50% instead of 100%.
Another difference between Brg1+/−;Brm−/− and Brg1−/− embryos is the specific timing of
their peri-implantation phenotype. When we performed double-heterozygous intercrosses
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and flushed embryos from the uterine tract after the onset of implantation at E5.0,
Brg1+/−;Brm−/− embryos were not underrepresented (7 observed compared to 8 expected).
This suggests that Brg1+/−;Brm−/− embryos do not exhibit delayed implantation or a failure
to implant. In contrast, previous experiments with Brg1 intercrosses indicated that Brg1−/−
embryos were overrepresented under the same conditions (Bultman et al 2000), suggesting
that they do not implant normally.
The J1 antibody used to biochemically purify esBAF binds more strongly to BRG1 than
BRM Our blastocyst outgrowth experiments suggest that the combined gene dosage
requirement for Brg1 and Brm applies to both the ICM and the trophectoderm. The ICM
result was initially surprising because SWI/SNF complexes in ES cells, referred to as
esBAF, incorporate only BRG1 as the catalytic subunit rather than either BRG1 or BRM
(Ho et al 2009a, Ho et al 2009b). To reconcile this apparent discrepancy, we hypothesized
that a subset of esBAF complexes might be catalyzed by BRM but were not detected in the
biochemical purification experiments for biological and technical reasons. Biologically, Brm
is expressed at much lower levels than Brg1 in ES cells and in the ICM from which they are
derived (Bultman et al 2000, LeGouy et al 1998). Technically, the biochemical purification
of esBAF involved an affinity purification step using a BRG1 antibody (J1), and its capacity
to cross-react with BRM has not been characterized to our knowledge. Therefore, we
performed western blots on normal human fibroblasts (NHF1-hTERT) following the RNAi-
mediated knockdown of BRG1, BRM, or both BRG1 and BRM simultaneously (herein
referred to as double knockdowns). A validated BRG1-specific antibody (Santa Cruz G-7)
demonstrated that siBRG1 cells had only 6% of BRG1 levels compared to non-targeted
control (siNTC) cells after normalizing with tubulin (Figure 3, second row). This low signal
represented residual BRG1 protein rather than BRM cross-reactivity because the signal was
not further diminished in double-knockdown cells. In contrast, J1 yielded higher signal in
siBRG1 cells (37% relative to siNTC compared to 6% for α-BRG1 G-7), and some of this
signal was due to cross-reactivity to BRM because the signal dropped to 16% in double-
knockdown cells (Figure 3, top row). However, J1 clearly binds to BRG1 with higher
affinity than BRM, and quantification of these results suggest that J1 binds to BRM only
~15% as strongly as to BRG1. The limited cross-reactivity of J1 to BRM is reinforced by the
strong signal observed in siBRM cells. These cells had only 9% of BRM compared to
siNTC using a validated BRM-specific antibody (Abcam) after normalizing with tubulin
(Figure 3, third row), yet J1 signal was 107% in siBRM compared to siNTC. These results
strongly suggest that J1 would have preferentially isolated BRG1-catalyzed complexes in ES
cells even if BRG1 and BRM were of equal abundance (which they are not). Taken together,
these results suggest that BRM catalyzes a minority fraction of esBAF complexes that are
functional if BRG1 dosage is diminished.
Discussion
The results presented here demonstrate that the combined gene dosage of Brg1 and Brm is
crucial for mammalian development. When the combined gene dosage is diminished from
four copies in wild-type (Brg1+/+;Brm+/+) embryos to one copy in Brg1+/−;Brm−/− double-
mutant embryos, it falls below a threshold required for implantation to occur successfully on
a consistent basis. This finding is compatible with the idea that SWI/SNF complexes play a
particularly important role in peri-implantation development based on the phenotype of
Brg1, Snf5/Baf47, Baf155, and Baf250a/Arid1a null homozygotes. The Brg1+/−;Brm−/−
embryos that fail to develop appear to undergo the decidualization reaction and die shortly
after implantation. This phenotype is similar to Snf5/Baf47, Baf155, and Baf250a/Arid1a
null homozygotes but a little later than Brg1 null homozygotes that do not implant.
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The combined gene dosage requirement for Brg1 and Brm applies to both the ICM and the
trophectoderm based on blastocyst outgrowth assays. The ICM result was seemingly at odds
with biochemical data that BRG1 is the exclusive subunit of esBAF complexes. However,
our experiments demonstrating that the J1 antibody (which was used to biochemically purify
esBAF complexes) binds to BRG1 more strongly than BRM provides a plausible
explanation for this discrepancy. We propose that a minority fraction of esBAF complexes
are catalyzed by BRM. To keep this catalytic subunit heterogeneity in perspective, however,
BRG1 is clearly more important than BRM for esBAF function. Not only is BRG1 more
abundant than BRM in ES cells and in the early embryo, but 100% of Brg1−/− blastocysts
fail to implant compared to 0% for Brm−/−. It is only when Brg1 is heterozygous that Brm is
a factor with ~50% of Brg1+/−;Brm−/− blastocysts failing to develop beyond the
implantation stage.
The results presented here support a previous study demonstrating that Brg1−/− and Brm−/−
mouse embryo fibroblasts (MEFs) can survive, whereas Brg1−/−;Brm−/− MEFs are not
viable (Wang et al 2009). Therefore, in addition to Brg1 being able to compensate for Brm,
Brm can compensate for Brg1. However, the combined gene dosage of Brg1 and Brm are
functionally important in certain cell types but not in others. For example, Brg1
heterozygotes are susceptible to exencephaly (Bultman et al 2000), which results in peri-
natal lethality, but Brm heterozygosity or homozygosity did not increase the penetrance or
expressivity of this phenotype. It is not clear why this is the case. Baf155 heterozygotes are
also predisposed to exencephaly, and this phenotype was associated with decreased cell
proliferation during neural tube closure (Kim et al 2001). One possibility is that BRG1-
catalyzed complexes are primarily utilized in highly proliferative cells during embryonic
development, while BRG1- and BRM-catalyzed complexes are utilized to a similar extent in
more differentiated cell types in adult tissues. This idea is consistent with the relative
expression levels of BRG1 and BRM since the former is enriched in highly proliferative cell
types that self renew, while the later is enriched in more differentiated cell types that do not
proliferate to the same extent (Reisman et al 2005). This idea is further supported by
functional studies of Brg1 and Brm in vascular endothelial cells (VEC) during their
development, when they are relatively highly proliferative, as well as in adults when they
are less proliferative. Brg1Tie2-Cre conditional mutants are embryonic lethal (Griffin et al
2008, Stankunas et al 2008), and the phenotype of the developing VECs was not more
severe on a Brm-deficient background (Griffin et al 2008). In contrast, an inducible mutation
of Brg1 in adult VECs did not confer an observable phenotype on a wild-type background
but resulted in rapid cell death and organismal death on a Brm-deficient background (Willis
et al 2012).
However, arguing against this possibility is the data presented here on peri-implantation
embryos and blastocyst outgrowths since the epiblast is highly proliferative and sensitive to
the dosage of both Brg1 and Brm. Additional evidence for the importance of BRM dosage in
development comes from whole exome sequencing projects that recently identified recurrent
loss-of-function mutations in BRM and BAF250B/ARID1B that cause human syndromes
with similar phenotypic spectrums that include intellectual disability, altered craniofacial
features, and distal limb anomalies (Santen et al 2012, Van Houdt et al 2012). All of these
mutations occurred de novo and were therefore heterozygous, which implies that the
corresponding gene products are dosage sensitive. These findings support the idea that the
dosage of SWI/SNF subunits is crucial for human development. This may explain why
germline homozygous null mutations of human SWI/SNF genes have not been reported;
they are likely so deleterious that they would be lethal in utero as they are in mice.
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Runting of Brg1+/−;Brm−/− mice. Weight of weaning-age mice from 14 litters of double-
heterozygous intercrosses. The weights of Brg1+/−;Brm−/− mice are compared to the other 5
genotypes.
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Brg1+/−;Brm−/− blastocysts give rise to an increased percentage of abnormal outgrowths. (A,
B) Brightfield photographs of normal (A) and abnomal (B) blastocyst outgrowths after 7
days in culture. (A) Normal blastocysts outgrowths hatched from the zona pellucida (ZP),
the trophectoderm (TE) attached to and spread out across the bottom of the tissue culture
wells, and the inner cell masses (ICM) underwent extensive cell proliferation. (B) Abnormal
blastocyst outgrowths failed to hatch from the zona pellucida and died. Pyknotic blastomeres
are evident (arrow). (C) Normal and abnormal blastocyst outgrowths for each of the 6
genotypic categories. The percentage value in the abnormal column refers to the percentage
of abnormal outgrowths.
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Characterization of J1 antibody binding to BRG1 and BRM. (A)Representative western blot
of protein lysates from normal human fibroblasts (NHF1-hTERT) following depletion of
BRG1 and BRM, alone and in combination, by RNAi using specific siRNAs as indicated at
the top. The first lane is a non-targeted control (NTC) siRNA. Protein lysates were probed
with the J1 antibody (top panel), antibodies specific for BRG1 (second panel) or BRM (third
panel), and Tubulin (bottom panel) as a loading control. (B) Quantification of BRG1 and
BRM levels from western blot above. Protein levels detected by J1, α-BRG1, and α-BRM
in siNTC, siBRG1, siBRM, and siBRG1 + siBRM cells are shown. All values were
normalized with α-Tubulin and are relative to the siNTC control (set at 100).
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Table 1
Mouse Brg1 allelic series
Mutant Allele Tissue(s) Phenotype Reference(s)
Null (constitutive) All −/− peri-implantation lethality
+/− exencephaly and mammary tumors with
incomplete penetrance
Bultman et al. 2000
Bultman et al. 2008
ENU1 (constitutive)
Hypomorph (E1083G)
All Null/ENU1 E12.5 lethality, anemia associated
with globin and replication defects ENU1/ENU1
post-natal failure to thrive
Bultman et al. 2005
Kim et al. 2007, 2009a, 2009b
Cohen et al. 2010
Zp3-Cre Oocytes Maternal effect: progeny exhibit 2-cell arrest
associated with ZGA defect
Bultman et al. 2006
Tie2-Cre VECs E11.5 lethality associated with yolk sac
angiogenesis defects
Griffin et al. 2008, 2011
Stankunas et al. 2008
Curtis and Griffin 2012
Lck-Cre T cells DN-DP block in thymus, CD4 derepression,
intestinal inflammation
Gebuhr et al. 2003
Chi et al. 2003
Lck-Cre Knock-in
Antimorph (K785R)
T cells T cell defect with similarities and differences
compared to conditional null
Jani et al. 2008
Nestin-Cre Neuronal progenitors Neuronal differentiation defects and early
postnatal lethality
Matsumoto et al. 2006
Lessard et al. 2007
Sm22α-Cre Cardiomyocytes Lethality just after E11.5 associated with
proliferation defect; inducible mutation prevents
MHC switch from occurring in adults in response
to hypertrophy
Hang et al. 2010
Nkx2.5-Cre Cardiomyocytes Cardiac defects with lethality mostly at E10.5 but
with some survivors
Takeuchi et al. 2011
Mhv-Cre Germ cells Synaptic defects and meiotic arrest of
spermatocytes
Kim et al. 2012
Mx1-Cre VEC, HSC, liver Lethal cardiovascular defect within ~1 month of
mutation induction if also Brm−/−
Willis et al. 2012
Wap-Cre Mammary, ovary, uterus No mammary tumors but ovarian cysts and uterine
tumors
Serber et al. 2012
K14-Cre Keratinocytes and epithelial
cells
Peri-natal lethality due to dehydration from skin
barrier permeability impairment; limb
malformations due to AER defect during
development
Indra et al. 2005
Dhh-Cre Schwann cells Neuropathy due to Schwann cell differentiation
and myelination defect
Welder et al. 2012
Le-Cre Eye Microphthalmia and other eye defects He et al. 2010
smMHC-Cre Smooth muscle Lethality associated with smooth muscle defects in
cardiovascular, pulmonary, and other sites
including GI tract
Zhang et al. 2012
-Note: does not include RNAi experiments or expression of dominant-negative BRG1 in tissue-culture cells including ES cells, which have been
important for showing a role in processes such as pluripotency and muscle cell differentiation (for example, de la Serna et al. 2001).
-All mutant alleles are conditional nulls unless indicated otherwise.
-Abbreviations: ZGA, zygotic genome activation; VEC, vascular endothelial cell; DN, double negative (CD4−CD8−); DP, double positive
(CD4+CD8+); MHC, myosin; heavy chain; HSC, hematopoitic stem cells; AER, apical ectodermal ridge; consult references for gene names of
promoters used to drive Cre.













Smith-Roe and Bultman Page 15
Table 2
Genotype of live-born progeny obtained from Brg1-Brm double heterozygous intercrosses
Genotype Expected^ Observed# Observed/Expected
Brg1 Brm
+/+ +/+ .107 108 (.163) 1.52***
+/+ +/− .213 144 (.218) 1.02
+/+ −/− .107 87 (.131) 1.22*
+/− +/+ .144 109 (.165) 1.14
+/− +/− .286 156 (.236) 0.83**
+/− −/− .144 58 (.088) 0.61***
#
A total of 662 mice were genotyped at weaning.
^
Because Brg1−/− is lethal, no mice were observed for this genotype regardless of Brm genotype (+/+, +/−, or −/−), and the absence of these mice
were taken into account when determining the expected genotypic frequencies. In addition, Brg1 heterozygotes are underrepresented due to







p < 0.001 based on chi-squared goodness-of-fit statistical tests.
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Table 4
Genotype of E5.5–8.5 embryos obtained from Brg1-Brm double heterozygous intercrosses
Genotype Expected^ Observed# Observed/Expected
Brg1 Brm
+/+ +/+ 1/12 (.083) 21 (.150) 1.8**
+/+ +/− 2/12 (.167) 31 (.221) 1.3
+/+ −/− 1/12 (.083) 14 (.100) 1.2
+/− +/+ 2/12 (.167) 21 (.150) 0.90
+/− +/− 4/12 (.333) 39 (.279) 0.84
+/− −/− 2/12 (.167) 14 (.100) 0.60*
#
A total of 140 embryos were genotyped. 11 empty deciduae were observed that could not be genotyped due to maternal contamination.
^
Because Brg1−/− is lethal prior to implantation, no embryos were observed for this genotype regardless of Brm genotype (+/+, +/−, or −/−), and
the absence of these mice were taken into account when determining the expected genotypic frequencies.
*
p < 0.05 and
**
p < 0.005 based on chi-squared goodness-of-fit statistical tests.
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